ClinicalTrials.gg
CompletedNCT03277196Updated Oct 23, 2024Results posted

A Study to Evaluate the Safety of Long-term Ivacaftor Treatment in Participants With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have an Approved Ivacaftor-Responsive Mutation

A Phase 3 interventional study of IVA in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 29 sites in 6 countries. Open to participants aged 0 Months to 24 Months. Per ClinicalTrials.gov, last updated 2024-10-23.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
86
Allocation
Non-randomized
Ages
0 Months to 24 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 84 studies testing ivacaftor in Cystic Fibrosis — 4 open to participants now, 7 under way, 2 of them phase 3. ivacaftor · Cystic Fibrosis.

Enrollment
32nd of 84
86 · median 70
Started
2017
with 6 others
Phase 3
45 of 84
none open now
Registered
52nd of 84
by date
Lead sponsor
74 of 84
Vertex Pharmaceuticals Incorporated

Among the 84 studies testing ivacaftor in Cystic Fibrosis, this one is the 32nd largest by enrollment, is one of 7 that started in 2017, is one of 45 in phase 3, and was the 52nd registered.

Cystic Fibrosis

1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

4 of the 84 studies testing ivacaftor in Cystic Fibrosis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About ivacaftor

ivacaftor: first FDA approval 2012 (KALYDECO), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.

This study: 0 Months to 24 Months · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 84 studies testing ivacaftor in Cystic Fibrosis, or all of them as a file.
02

Study summary

This is a Phase 3, 2-arm, multicenter study with an open-label ivacaftor arm and an observational arm to evaluate the safety and efficacy of long-term ivacaftor treatment in participants with cystic fibrosis (CF) who are \<24 months of age at treatment initiation and have an approved Ivacaftor-Responsive mutation.

03

Conditions studied

  • Cystic Fibrosis

Browse trials for

04

Who can participate

Ages eligible
0 Months to 24 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Ivacaftor Arm: Participants From Study 124 (NCT02725567 ) Part B:

  • Participants transitioning from Study 124 Part B must have completed the last study visit of Study 124 Part B.
  • As judged by the investigator, parent or legal guardian must be able to understand protocol requirements, restrictions, and instructions; and must sign the form (ICF).

Ivacaftor Arm: Participants Not From Study 124 Part B:

  • Confirmed diagnosis of CF, or 2 CF-causing mutations.
  • An ivacaftor- responsive CFTR mutation on at least 1 allele. Participants will be eligible in countries/regions where ivacaftor is approved for use in participants 2 years of age and older.
  • As judged by the investigator, parent or legal guardian must be able to understand protocol requirements, restrictions, and instructions; and must sign the ICF.

Observational Arm:

  • Received ivacaftor treatment in Study 124 Part B and elected not to enroll or ineligible to enroll in the ivacaftor arm of Study 126.

Exclusion criteria

Exclusion Criteria:

Ivacaftor Arm: Participants From Study 124 Part B:

  • History of any illness or condition that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering ivacaftor to the participant.
  • Participants receiving commercially available ivacaftor treatment

Ivacaftor Arm: Participants Not From Study 124 Part B:

  • History of any illness or condition that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering ivacaftor to the participant
  • An acute upper or lower respiratory infection, or pulmonary exacerbation, or changes in therapy for pulmonary disease within 4 weeks of Day 1
  • Abnormal liver function at screening
  • \<9.5 g/dL at screening
  • History of solid organ or hematological transplantation
  • Use of any moderate or strong inducers or inhibitors of within 2 weeks of Day 1

Observational Arm:

  • Receiving ivacaftor treatment

Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
86 participants (actual)

Study arms

  • Experimental
    Ivacaftor Arm

    Participants less than (\<) 24 months of age and weighing 5 to less than (\<) 7 kilogram (kg) received 25 mg IVA every 12 hours (q12h), 7 to \<14 kg received 50 mg IVA q12h, and those weighing 14 to \<25 kg received 75 mg IVA q12h. Participants more than or equal (\>=) 24 months of age and weighing \<14 kg received 50 mg IVA q12h, and those weighing more than or equal to (\>=)14 kg received 75 mg IVA q12h in the treatment period for up to 96 weeks. Doses were determined based on safety and pharmacokinetic (PK) data from parent study, age and weight.

    Drug: IVA

  • No intervention
    Observational Arm

Interventions

  • DrugIVA

    Granules for oral administration.

    Also known as: VX-770, ivacaftor

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs

    Time frame: Day 1 up to Week 120

Secondary outcomes

  1. Absolute Change in Sweat Chloride

    Sweat samples were collected using an approved collection device.

    Time frame: From Baseline at Week 96

07

Results

Posted Oct 23, 2024

Participant flow

This study was planned to include 2 arms: an ivacaftor (IVA) arm (open-label, 96-week treatment period) and an observational arm. However, there were no participants enrolled in the observational arm. A total of 86 participants enrolled in the Ivacaftor arm.

Participant flow — Overall Study
MilestoneIvacaftor Treatment
Started86
Rollover participants38
Iva-naïve participants48
Completed58
Not completed28
Withdrew: Commercial drug is available for participants20
Withdrew: Lost to follow-up3
Withdrew: Withdrawal of consent (not due to ae)3
Withdrew: Other2

Outcome measures

PrimarySafety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs
Time frame:
Day 1 up to Week 120
Reported as:
Count of participants · Participants
Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs
ParticipantsIvacaftor Treatment
Participants with TEAEs85
Participants with SAEs21
SecondaryAbsolute Change in Sweat Chloride

Sweat samples were collected using an approved collection device.

Time frame:
From Baseline at Week 96
Reported as:
Mean · millimole per liter (mmol/L)
Absolute Change in Sweat Chloride
millimole per liter (mmol/L)Ivacaftor Treatment
Absolute Change in Sweat Chloride-55.3 ± 25.0

Adverse events

Collected over Day 1 up to Week 120. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ivacaftor Arm0/86 (0%)21/86 (24.4%)83/86 (96.5%)
Most frequent serious events
Showing 10 of 23
Most frequent serious events
EventIvacaftor Arm
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations9/86
ConstipationGastrointestinal disorders2/86
Pseudomonas test positiveInvestigations2/86
Adrenocortical insufficiency acuteEndocrine disorders1/86
Distal intestinal obstruction syndromeGastrointestinal disorders1/86
PyrexiaGeneral disorders1/86
BronchiolitisInfections and infestations1/86
BronchitisInfections and infestations1/86
GastroenteritisInfections and infestations1/86
Gastroenteritis viralInfections and infestations1/86
Most frequent other events
Showing 10 of 28
Most frequent other events
EventIvacaftor Arm
CoughRespiratory, thoracic and mediastinal disorders60/86
PyrexiaGeneral disorders34/86
RhinorrhoeaRespiratory, thoracic and mediastinal disorders33/86
Upper respiratory tract infectionInfections and infestations24/86
VomitingGastrointestinal disorders22/86
RashSkin and subcutaneous tissue disorders21/86
Ear infectionInfections and infestations19/86
DiarrhoeaGastrointestinal disorders15/86
ConstipationGastrointestinal disorders13/86
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations13/86

Baseline characteristics

Baseline data was analyzed on safety Set which is defined as all participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(months)Ivacaftor Treatment
Mean10.2 ± 5.19
Sex: Female, Male
Sex: Female, Male(Participants)Ivacaftor Treatment
Female40
Male46
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Ivacaftor Treatment
Hispanic or Latino2
Not Hispanic or Latino79
Not collected per local regulations5
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Ivacaftor Treatment
White82
Asian1
Not collected per local regulations3
08

Study locations

29 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35233, United States
  • Stanford University
    Palo Alto, California 94034, United States
  • Alfred I DuPont Hospital for Children
    Wilmington, Delaware 19803, United States
  • Nemours Children's Hospital
    Orlando, Florida 32827, United States
  • Center for Advanced Pediatrics
    Atlanta, Georgia 30329, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • Riley Hospital for Children at Indiana University Health
    Indianapolis, Indiana 46202, United States
  • John Hopkins Hospital
    Baltimore, Maryland 21287, United States
  • Boston Children's Hospital
    Boston, Massachusetts 02115, United States
  • Childrens's Hospitals and Clinics of Minnnesota
    Minneapolis, Minnesota 55404, United States
  • Children's Mercy Hospital
    Kansas City, Missouri 64108, United States
  • Billings Clinic Hospital
    Billings, Montana 59101, United States
  • Nationwide Children's Hospital
    Columbus, Ohio 43205, United States
  • Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • Texas Children's Hospital
    Houston, Texas 77030, United States
  • Seattle Children's Hospital
    Seattle, Washington 98105, United States
  • University of Wisconsin
    Madison, Wisconsin 53792, United States
  • Queensland Children's Hospital
    South Brisbane, Australia
  • The Hospital for Sick Children
    Toronto, Ontario, Canada
  • Universitaetsklinikum Heidelberg, Zenter fuer Kinder-und Jugendmedizin
    Heidelberg, Germany
  • Children's Health Ireland at Crumlin
    Dublin, Ireland
  • Children's University Hospital Temple Street
    Dublin, Ireland
  • University Hospital Limerick
    Limerick, Ireland
  • Paediatric Clinical Research Facility
    Edinburgh, United Kingdom
  • Alder Hey Children's Alder Hey Children's NHS Foundation Trust
    Liverpool, United Kingdom
  • Great Ormond Street Hospital for Sick Children
    London, United Kingdom
  • Royal Brompton & Harefield NHS Founcation Trust, Royal BromptonHospital
    London, United Kingdom
  • Royal Manchester Children's Hospital
    Manchester, United Kingdom
  • Oxford University Hospitals NHS Trust, John Radcliffe Hospital
    Oxford, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent-research/clinical-trial-data-sharing

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2017 to primary completion in Oct 2023, 73 months.

Results were first posted in Oct 2024, 1 year after primary completion.

Of 58 industry-sponsored phase 3 interventional studies under Cystic Fibrosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 36. This study's 73 months is above that.

Counting every sponsor, half of 67 studies reached it within 26 months; a quarter within 16 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2017
First posted
Sep 8, 2017
StartActual
Aug 16, 2017
Primary completionActual
Oct 2, 2023
CompletionActual
Oct 2, 2023
Results first posted
Oct 23, 2024
Last update
Oct 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03277196
Responsible party
Sponsor
First posted
Sep 8, 2017
Start date
Aug 16, 2017
Primary completion
Oct 2, 2023
Completion
Oct 2, 2023
Results posted
Oct 23, 2024
Last update
Oct 23, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ivacaftor

Start the discussion